Summary
-
1.
Metoclopramide, a drug with blocking activity at peripheral neuronal receptor sites for 5-hydroxytryptamine (5-HT), was investigated as an antagonist of the ‘Wet-Dog’ shake response (WDS) to injections of 5-hydroxytryptophan (5-HTP) in rats. Its effects were compared with those of methysergide, an antagonist of 5-HT at non-neuronal receptor sites, and haloperidol, a dopamine receptor antagonist.
-
2.
WDS after 5-HTP and carbidopa, an inhibitor of peripheral aromatic l-amino acid decarboxylase, correlates significantly with the increase in whole brain 5-HT concentrations measured in parallel experiments.
-
3.
Metoclopramide, methysergide and haloperidol inhibited WDS. Metoclopramide, in addition, inhibited the increase in brain 5-HT, but not, apparently, by interfering with the decarboxylase enzyme.
-
4.
Inhibition of the rise in brain 5-HT could not explain inhibition of WDS by metoclopramide, since metoclopramide inhibited 5-HTP-induced shaking once established and also the response to quipazine, a directly-acting agonist at central 5-HT receptors.
-
5.
The mechanism of action of methysergide may involve blockade of post-synaptic receptor sites for 5-HT. Metoclopramide and haloperidol, on the other hand, cause catalepsy at doses which inhibit WDS, presumably through blockade of dopamine receptors in the CNS. The consequent inhibition of the ability of the animals to initiate movement may be the mechanism by which these compounds inhibit WDS.
-
6.
Since agents with cataleptic properties, probably unconnected to brain 5-HT mechanisms, are effective antagonists of the shaking response, WDS after 5-HTP may be less useful than previously supposed as a screen for durgs interacting with 5-HT receptors in the CNS.
Similar content being viewed by others
References
Ahtee, L.: Inhibition by apomorphine of the metoclopramide-induced catalepsy and increase in striatal homovanillic acid content. Br. J. Pharmacol. 55, 381–385 (1975)
Bédard, P., Pycock, C. J.: ‘Wet-Dog’ shake behaviour in the rat: a possible quantitative model of central 5-HT activity. Neuropharmacology 16, 663–670 (1977)
Bennett, J. P., Snyder, S. H.: Serotonin and lysergic acid diethylamide binding in rat brain membranes: relationship to postsynaptic serotonin receptors. Mol. Pharmacol. 12, 373–389 (1975)
Borenstein, P., Bles, G.: Effets cliniques et électroencéphalographiques du métoclopramide en psychiatrie. Thérapie 20, 975–995 (1965)
Carr, S. R., Fozard, J. R.: Investigation of the antagonism by apomorphine of the sympathomimetic response to 5-HT in perfused rabbit heart. Abstract 2033, Proceedings of the 7th International Congress of Pharmacology, Paris, 1978
Carter, C. J., Pycock, C. J.: Possible importance of 5-hydroxytryptamine in neuroleptic-induced catalepsy in rats. Br. J. Pharmacol. 60, 267 P (1977)
Carter, C. J., Pycock, C. J.: A study of the sites of interaction between dopamine and 5-hydroxytryptamine for the production of fluphenazine-induced catalepsy. Naunyn-Schmiedeberg's Arch. Pharmacol. 304, 135–139 (1978)
Costall, B., Naylor, R. J.: Neuroleptic and non-neuroleptic catalepsy. Arzneimittel-Forsch. 23, 674–683 (1973)
Douglas, W. W.: Histamine and antihistamines: 5-hydroxytryptamine and antagonists. In: The pharmacological basis of therapeutics (L. S. Goodman and A. Gilman, eds.), pp. 590–629. New York: Macmillan 1975
Elliott, P. N. C., Jenner, P., Huizing, G., Marsden, C. D., Miller, R.: Substituted benzamides as cerebral dopamine antagonists in rodents. Neuropharmacology 16, 333–342 (1977)
Fontaine, J., Reuse, J. J.: Action du métoclopramide et de la procaine sur des bandelettes fundiques isolées d'estomac de rat. Arch. Int. Pharmacodyn. Ther. 204, 191–195 (1973)
Fozard, J. R.: The animal pharmacology of drugs used in the treatment of migraine. J. Pharm. Pharmacol. 27, 297–321 (1975)
Fozard, J. R., Mobarok Ali, A. T. M.: Blockade of neuronal tryptamine receptors by metoclopramide. Eur. J. Pharmacol. 49, 109–112 (1978a)
Fozard, J. R., Mobarok Ali, A. T. M.: Receptors for 5-hydroxytryptamine on the sympathetic nerves of the rabbit heart. Naunyn-Schmiedeberg's Arch. Pharmacol. 301, 223–235 (1978b)
Fozard, J. R., Palfreyman, M. G.: Metoclopramide antagonism of 5-hydroxytryptophan-induced ‘Wet-Dog’ shake behaviour in the rat. Br. J. Pharmacol. 63, 387P-388P (1978)
Grabowska, M., Antikiewicz, L., Michaluk, J.: A possible interaction of quipazine with central dopamine structures. J. Pharm. Pharmacol. 26, 74–76 (1974)
Greene, A. R., Youdim, M. B. H., Grahame-Smith, D. G.: Quipazine; its effects on rat brain 5-HT metabolism, monoamineoxidase activity and behaviour. Neuropharmacology 15, 173–179 (1976)
Jacoby, J. H., Poulakos, J. J.: The actions of neuroleptic drugs and putative serotonin receptor antagonists on LSD and quipazine-induced reductions of brain 5-HIAA concentrations. J. Pharm. Pharmacol. 29, 771–773 (1977)
Jacoby, J. H., Poulakos, J. J., Bryce, G. F.: On the central antiserotoninergic actions of cyproheptadine and methysergide. Neuropharmacology 17, 299–306 (1978)
Justin-Besançon, L., Laville, C.: Action anti-émétique du métoclopramide vis-à-vis de l'apomorphine et de l'hydergine. C. r. Soc. Biol. (Paris) 158, 723–727 (1964)
Lal, H., Newman, R.: Blockade of morphine-withdrawal body shakes by haloperidol. Life Sci. 18, 163–167 (1976)
Middlemiss, D. N., Blakeborough, L., Leather, S. R.: Direct evidence for an interaction of β-adrenergic blockers with the 5-HT receptor. Nature (Lond.) 267, 289–290 (1977)
Nakra, B. R. S., Bond, A. J., Lader, M. H.: Comparative psychotropic effects of metoclopramide and prochlorperazine in normal subjects. J. Clin. Pharmac. 15, 449–454 (1975)
Peringer, E., Jenner, P., Donaldson, I. M., Marsden, C. D., Miller, R.: Metoclopramide and dopamine receptor blockade. Neuropharmacology 15, 463–469 (1976)
Palfreyman, M. G., Danzin, C., Bey, P., Jung, M. J., Ribereau-Gayon, G., Aubry, M., Vevert, J.-P., Sjoerdsma, A.: α-Difluoromethyldopa, a new enzyme-activated irreversible inhibitor of aromatic l-amino acid decarboxylase. J. Neurochem. 31, 927–932 (1978)
Rodriguez, R., Rojas-Ramirez, J. A., Drucker-Colin, R. R.: Serotonin-like actions of quipazine on the CNS. Eur. J. Pharmacol. 24, 164–171 (1973)
Snyder, S. H., Axelrod, J., Zweig, M.: A sensitive and specific fluorescence assay for tissue serotonin. Biochem. Pharmacol. 14, 831–835 (1965)
Sofia, R. D., Vassar, H. B.: The effect of ergotamine and methysergide on serotonin metabolism in the rat brain. Arch. Int. Pharmacodyn. Ther. 216, 40–50 (1975)
Udenfriend, S., Zaltzman-Nirenberg, P., Gordon, R., Spector, S.: Evaluation of the biochemical effects produced in vivo by inhibitors of the three enzymes involved in norepinephrine biosynthesis. Molec. Pharmac. 2, 95–105 (1966)
Von Hungen, K., Roberts, S., Hill, D. F.: Serotonin sensitive adenylate cyclase activity in immature rat brain. Brain Res. 84, 257–267 (1975)
Wei, E. T.: Chemical stimulants of shaking behaviour. J. Pharm. Pharmacol. 28, 722–724 (1976)
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Fozard, J.R., Palfreyman, M.G. Metoclopramide antagonism of 5-hydroxytryptophan-induced “Wet-Dog” shake behaviour in the rat. Naunyn-Schmiedeberg's Arch. Pharmacol. 307, 135–142 (1979). https://doi.org/10.1007/BF00498455
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00498455